Voya Investment Management LLC Has $16.58 Million Holdings in Krystal Biotech, Inc. $KRYS

Voya Investment Management LLC raised its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 46.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 93,908 shares of the company’s stock after purchasing an additional 29,915 shares during the period. Voya Investment Management LLC’s holdings in Krystal Biotech were worth $16,578,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. State Street Corp boosted its holdings in shares of Krystal Biotech by 10.5% during the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after purchasing an additional 128,639 shares during the period. Soleus Capital Management L.P. grew its holdings in shares of Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after acquiring an additional 481,200 shares in the last quarter. Braidwell LP increased its stake in shares of Krystal Biotech by 81.6% in the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock worth $100,045,000 after acquiring an additional 327,067 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Krystal Biotech by 1.2% during the second quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock worth $85,174,000 after acquiring an additional 7,194 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after purchasing an additional 365,304 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total value of $5,504,000.00. Following the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. The trade was a 1.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 13.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have weighed in on KRYS. Chardan Capital upped their target price on Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Citigroup raised their price objective on shares of Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 15th. HC Wainwright restated a “buy” rating and set a $240.00 price target on shares of Krystal Biotech in a report on Monday, September 15th. Finally, Bank of America lifted their price objective on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $228.14.

Krystal Biotech Trading Up 3.7%

NASDAQ KRYS opened at $249.61 on Tuesday. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $249.78. The company has a fifty day simple moving average of $210.67 and a 200 day simple moving average of $171.72. The company has a market cap of $7.24 billion, a P/E ratio of 37.42 and a beta of 0.48.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. The firm had revenue of $97.80 million during the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. Equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.